HC Wainwright Predicts Indivior’s Q3 Earnings (NASDAQ:INDV)

Indivior PLC (NASDAQ:INDV) – Equities research analysts at HC Wainwright increased their Q3 2026 EPS estimates for Indivior in a note issued to investors on Tuesday, August 4th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $0.93 for the quarter, up from their previous estimate of $0.78. HC Wainwright also issued estimates for Indivior’s Q4 2026 earnings at $1.07 EPS, FY2026 earnings at $3.66 EPS, FY2027 earnings at $3.83 EPS, FY2028 earnings at $3.99 EPS, FY2029 earnings at $4.22 EPS and FY2030 earnings at $4.46 EPS.

A number of other equities analysts also recently weighed in on the stock. Weiss Ratings raised shares of Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 24th. Barclays reduced their price objective on Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $53.00 target price on shares of Indivior in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.17.

Indivior Stock Up 6.1%

INDV stock opened at $38.73 on Thursday. The company has a 50 day moving average of $39.18 and a two-hundred day moving average of $35.57. The company has a market cap of $4.57 billion, a price-to-earnings ratio of 13.88 and a beta of 0.86. Indivior has a 12-month low of $21.48 and a 12-month high of $42.81.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. The firm had revenue of $343.00 million for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%.

Hedge Funds Weigh In On Indivior

Several institutional investors have recently bought and sold shares of the stock. Yousif Capital Management LLC acquired a new stake in shares of Indivior in the fourth quarter worth $1,137,000. Vanguard Group Inc. lifted its position in Indivior by 57.9% during the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after acquiring an additional 2,008,078 shares during the last quarter. Sandro Wealth Management LLC bought a new stake in Indivior during the fourth quarter valued at about $1,313,000. State of Alaska Department of Revenue bought a new stake in Indivior during the fourth quarter valued at about $2,279,000. Finally, Oregon Public Employees Retirement Fund acquired a new stake in shares of Indivior in the fourth quarter valued at about $1,026,000. 60.33% of the stock is currently owned by institutional investors.

Insider Transactions at Indivior

In related news, CFO Ryan Preblick sold 36,000 shares of Indivior stock in a transaction on Monday, June 8th. The shares were sold at an average price of $37.70, for a total value of $1,357,200.00. Following the completion of the sale, the chief financial officer owned 284,751 shares of the company’s stock, valued at approximately $10,735,112.70. The trade was a 11.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson acquired 1,500 shares of Indivior stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $36.28 per share, with a total value of $54,420.00. Following the purchase, the chief accounting officer owned 26,138 shares in the company, valued at $948,286.64. The trade was a 6.09% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.74% of the stock is currently owned by company insiders.

More Indivior News

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: Analyst estimates raised materially: HC Wainwright increased its EPS forecasts for every reported period, including FY2026 to $3.66 from $3.08, FY2027 to $3.83 from $3.34, FY2028 to $3.99 from $3.48, FY2029 to $4.22 from $3.70 and FY2030 to $4.46 from $3.93. Its Q3 and Q4 2026 estimates also rose to $0.93 and $1.07, respectively, signaling stronger anticipated earnings momentum.
• Positive Sentiment: Merger and operating performance support the outlook: Indivior announced plans to merge with Supernus Pharmaceuticals to create a CNS-focused biopharmaceutical company. The company also reportedly exceeded second-quarter earnings and revenue expectations and raised its 2026 outlook. Indivior merger, earnings and outlook article
• Positive Sentiment: Insider purchase: Chief Accounting Officer Woodrow Anderson bought 1,500 shares for approximately $54,420, increasing his direct holdings by 6.09%. The purchase may be viewed as a modest vote of confidence in Indivior’s valuation and prospects. Indivior insider purchase article
• Neutral Sentiment: Analyst sentiment remains favorable overall, with five Buy ratings and two Holds and a consensus “Moderate Buy” recommendation. However, Barclays lowered its price target to $43 while maintaining an Overweight rating; the consensus target is $45.17. Indivior analyst recommendation article

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.